Infections in Patients With Cytokine Release Syndrome/Immune Effector Cell–Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Therapy
Open Forum Infectious Diseases · 02.06.2026 · 13 (6)
DOI: 10.1093/ofid/ofag274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 10.06.2026. Verfasst von Antonio Gallardo-Pizarro und 19 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Department, Hospital Clinic of Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, European Union.
Abstract (Originalsprache)
Background
Cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) are common toxicities after chimeric antigen receptor (CAR) T-cell therapy. We evaluated the incidence, timing, microbiology, and risk factors of microbiologically documented infections during the CRS and/or ICANS phase.
Method
Consecutive adults receiving CAR T-cell therapy between 2020 and 2023 were retrospectively analyzed. Infections were classified by type and timing. The 60-day cumulative incidence of first infection and associated factors were assessed using Fine–Gray competing-risk models.
Results
Among 152 CAR T-cell infusions, CRS and/or ICANS occurred in 117 (77.0%) episodes, and 70 (59.8%) required immunomodulatory therapy. An infectious etiology was documented in 30 (25.6%) episodes, yielding 45 documented infections (21 bacterial [46.7%], 17 viral [37.8%], and 7 fungal [15.6%]), more frequent in immunomodulatory-treated episodes (32.9% vs 14.9%; P = .033). At infection onset, median temperature, and C-reactive protein (CRP) levels were lower than at CRS/ICANS diagnosis (37.2°C vs 38.4°C; P < .001 and 3.9 vs 6.0 mg/L; P = .002). In immunomodulatory-treated episodes, median time to first infection was 15 (7–22) days from CRS and 9 (5–20) days from ICANS. The 60-day cumulative infection incidence was 60.0% with multimodal immunosuppression and 20.8% without; multimodal immunosuppression independently increased infection risk (subdistribution hazard ratio [sHR] 3.29; 95% CI 1.38–7.82; P = .007).
Conclusions
The CRS/ICANS phase carries a high risk of bacterial, viral, and fungal infections, particularly under multimodal immunosuppression, while fever and CRP are unreliable indicators. Focused strategies for early detection, prevention, and prompt treatment of infections are urgently needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Infectious Disease Department, Hospital Clinic of Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.
- Department of Immunology, Hospital Clinic of Barcelona, Barcelona, Spain.
- Hematology Department, Hospital Clinic of Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Microbiology Department, Hospital Clinic of Barcelona, Institute for Global Health (ISGlobal), Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
ORCID-Profile: Antonio Gallardo-Pizarro, Miquel Ariño, Carlos Lopera, Ana Martinez-Urrea, Cynthia Terrones-Campos, Ainhoa Castiella-Aranzasti, E Azucena González-Navarro, Nil Albiol, Christian Teijon-Lumbreras, Cristina Pitart, M Ángeles Marcos, Valentín Ortíz-Maldonado, Josep Mensa, Julio Delgado, Álvaro Urbano-Ispizua, Carlos Fernández de Larrea, Alex Soriano, Nuria Martinez-Cibrian, Pedro Castro, Carolina Garcia-Vidal
Förderung
- Instituto de Salud Carlos III
- European Union
Zitieren
APA
Gallardo-Pizarro, A., Ariño, M., Lopera, C., Martinez-Urrea, A., Terrones-Campos, C., Castiella-Aranzasti, A., González-Navarro, E. A., Albiol, N., Teijon-Lumbreras, C., Pitart, C., Marcos, M. Á., Ortíz-Maldonado, V., Mensa, J., Delgado, J., Urbano-Ispizua, Á., Fernández de Larrea, C., Soriano, A., Martinez-Cibrian, N., Castro, P., & Garcia-Vidal, C. (2026). Infections in Patients With Cytokine Release Syndrome/Immune Effector Cell–Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Therapy. Open Forum Infectious Diseases, 13(6). https://doi.org/10.1093/ofid/ofag274
Vancouver
Gallardo-Pizarro A, Ariño M, Lopera C, Martinez-Urrea A, Terrones-Campos C, Castiella-Aranzasti A, et al. Infections in Patients With Cytokine Release Syndrome/Immune Effector Cell–Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Therapy. Open Forum Infectious Diseases. 2026;13(6). doi:10.1093/ofid/ofag274
BibTeX
@article{GallardoPizarro2026,
author = {Gallardo-Pizarro, Antonio and Ariño, Miquel and Lopera, Carlos and Martinez-Urrea, Ana and Terrones-Campos, Cynthia and Castiella-Aranzasti, Ainhoa and González-Navarro, E Azucena and Albiol, Nil and Teijon-Lumbreras, Christian and Pitart, Cristina and Marcos, M Ángeles and Ortíz-Maldonado, Valentín and Mensa, Josep and Delgado, Julio and Urbano-Ispizua, Álvaro and Fernández de Larrea, Carlos and Soriano, Alex and Martinez-Cibrian, Nuria and Castro, Pedro and Garcia-Vidal, Carolina},
title = {Infections in Patients With Cytokine Release Syndrome/Immune Effector Cell–Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Therapy},
journal = {Open Forum Infectious Diseases},
year = {2026},
volume = {13},
number = {6},
doi = {10.1093/ofid/ofag274}
}
EUVIMED